Antibody Therapy for Hemophilia A

Octomab - an improved antibody to treat Hemophilia A.

Our Why

People living with Hemophilia A depend on weekly, lifelong treatment.
Despite annual costs of up to 650,000€ per patient, current therapies still fall short.
We believe better treatment options are possible — and necessary.

Around 45,000 people in Europe live with Hemophilia A and require continuous, lifelong care. Existing treatments are effective but come with a high treatment burden and significant costs.

Our work is driven by the goal to improve treatment options and long-term outcomes for patients.

Disease Hemophilia A

Hemophilia A is a X-linked genetic disorder caused by a deficiency or dysfunction in the production of coagulation factor VIII. Factor VIII functions as a critical cofactor in the intrinsic coagulation pathway by activating factor X, which is necessary for the formation of thrombin and stable fibrin clots.

In Hemophilia A, the absence of functional factor VIII disrupts this cascade, resulting in clots that form slowly and are unstable. Consequently, patients with hemophilia A experience prolonged bleeding after injuries or spontaneous bleeding episodes without an apparent cause.

Octomab bridges FIXa and FX, bringing them into close proximity on the phospholipid membrane. This enables the activation of FX, allowing the coagulation cascade to continue despite the absence of factor VIII and thereby restoring effective clot formation.

Stronger Cells, Better Antibodies!

We combine advanced antibody engineering with targeted CHO cell line optimization to enable the efficient production of high-quality biotherapeutics. By integrating rational molecule design, improved secretion and folding capacity, and stable gene expression systems, we achieve robust manufacturing processes and consistent product quality. Our approach supports scalable, industry-relevant production of next-generation antibodies with enhanced efficacy and durability.